Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Zemanick, Edith T ^a   Harris, J Kirk ^a   Wagner, Brandie D ^b   Robertson, Charles E ^c   Sagel, Scott D ^a   Stevens, Mark J ^a   Accurso, Frank J ^a   Laguna, Theresa A ^d  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 8; LEUKOCYTE ELASTASE; ANTIINFECTIVE AGENT;

ADULT; AMPLICON; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG INFECTION; MALE; MICROBIAL DIVERSITY; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVOTELLA; PSEUDOMONAS; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SPUTUM EXAMINATION; STAPHYLOCOCCUS; ADOLESCENT; BACTERIUM; CLASSIFICATION; COMPLICATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; GENETICS; INFLAMMATION; LUNG FUNCTION TEST; METAGENOME; MICROBIOLOGY; PATHOPHYSIOLOGY; RESPIRATORY SYSTEM; SPUTUM; YOUNG ADULT;

PREVOTELLA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; CHILD; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; INFLAMMATION; MALE; METAGENOME; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM; SPUTUM; YOUNG ADULT;

EID: 84876999613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062917     Document Type: Article

References (55)

1. Gibson RL, Burns JL, Ramsey BW, (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918-951.
2. Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, et al. (2009) Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 103: 407-413.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, et al. (2001) Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 153: 345-352.
4. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH, (2011) Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 46: 393-400.
5. Goss CH, Burns JL, (2007) Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62: 360-367.
6. Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, et al. (2010) Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol 45: 569-577.
7. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, et al. (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182: 627-632.
8. Sibley CD, Rabin H, Surette MG, (2006) Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol 1: 53-61.
9. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, et al. (2004) Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 42: 5176-5183.
10. Bittar F, Rolain JM, (2010) Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect 16: 809-820.
11. Hamady M, Walker JJ, Harris JK, Gold NJ, Knight R, (2008) Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods 5: 235-237.
12. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, et al. (2007) Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A 104: 20529-20533.
13. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, et al. (2008) Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 3: e2908.
14. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, et al. (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177: 995-1001.
15. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, et al. (2011) Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66: 579-584.
16. Worlitzsch D, Rintelen C, Bohm K, Wollschlager B, Merkel N, et al. (2009) Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 15: 454-460.
17. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, et al. (2008) A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A 105: 15070-15075.
18. Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, et al. (2010) Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 12: 1293-1303.
19. Laguna TA, Wagner BD, Luckey HK, Mann SA, Sagel SD, et al. (2009) Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Chest 136: 1561-1568.
20. Laguna TA, Wagner BD, Starcher B, Luckey Tarro HK, Mann SA, et al. (2012) Urinary desmosine: A biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 47: 856-863.
21. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, et al. (2011) Relationship between lung microbiome, lung function and inflammation during treatment of CF pulmonary exacerbation. Pediatric Pulmonol Supplement 34: 306.
22. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr, (2010) Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 182: 1137-1143.
23. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW, (2010) Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 11: 137.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) Standardisation of spirometry. Eur Respir J 26: 319-338.
25. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, et al. (1998) Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27: 158-163.
26. Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K, (2007) Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol 73: 32-39.
27. Nadkarni MA, Caldon CE, Chhour KL, Fisher IP, Martin FE, et al. (2004) Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria. J Clin Microbiol 42: 5238-5244.
28. Harris JK, Sahl JW, Castoe TA, Wagner BD, Pollock DD, et al. (2010) Comparison of normalization methods for construction of large, multiplex amplicon pools for next-generation sequencing. Appl Environ Microbiol 76: 3863-3868.
29. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2008) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 36: D13-D21.
30. Frank DN, (2009) BARCRAWL and BARTAB: software tools for the design and implementation of barcoded primers for highly multiplexed DNA sequencing. BMC Bioinformatics 10: 362.
31. Nawrocki EP, Kolbe DL, Eddy SR, (2009) Infernal 1.0: inference of RNA alignments. Bioinformatics 25: 1335-1337.
32. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, et al. (2011) Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 21: 494-504.
33. Cole JR, Wang Q, Cardenas E, Fish J, Chai B, et al. (2009) The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 37: D141-D145.
34. Wang Q, Garrity GM, Tiedje JM, Cole JR, (2007) Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 73: 5261-5267.
35. Claesson MJ, O'Sullivan O, Wang Q, Nikkila J, Marchesi JR, et al. (2009) Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS ONE 4: e6669.
36. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
37. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, et al. (2007) SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res 35: 7188-7196.
38. Magurran AE (2004) Measursing Biological Diversity. Malden, MA: Blackwell Publishing Company.
39. Jost L, (2006) Entropy and Diversity. Oikos 113: 363-375.
40. Cohen J, Cohen P, West SG, Aiken LS (2003) Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Mahwah, NJ: Lawrence Earlbaum Associates.
41. Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, et al. (2003) Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 168: 1471-1475.
42. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, et al. (2005) Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 40: 15-21.
43. Parkins MD, Sibley CD, Surette MG, Rabin HR, (2008) The Streptococcus milleri group-an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatr Pulmonol 43: 490-497.
44. Eribe ER, Olsen I, (2008) Leptotrichia species in human infections. Anaerobe 14: 131-137.
45. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, et al. (2010) Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens. PLoS ONE 5: e15101.
46. Ulrich M, Beer I, Braitmaier P, Dierkes M, Kummer F, et al. (2010) Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 65: 978-984.
47. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, et al. (2006) Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 44: 2601-2604.
48. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, et al. (2012) Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Na,tl Acad Sci U S A 109: 13769-13774.
49. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, et al. (2010) Disordered microbial communities in asthmatic airways. PLoS ONE 5: e8578.
50. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, et al. (2011) Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE 6: e16384.
51. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, et al. (2010) Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 5: e11044.
52. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, et al. (2012) Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 109: 5809-5814.
53. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, et al. (2012) The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 7: e45001.
54. Daniels TW, Rogers GB, Stressmann FA, van der Gast CJ, Bruce KD, et al. (2012) Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros 12: 22-28.
55. Rogers GB, Marsh P, Stressmann AF, Allen CE, Daniels TV, et al. (2010) The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. Clin Microbiol Infect 16: 1656-1658.